Your one point of contact for Actelion services and support
Sure Steps™: Extensive education and support for every step of your patient's journey.
PAH Pathways Interactive Resource Locator
PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more ยป
To help support every step of your patient's journey with, PAH Pathways offers a patient education and support program we call Sure Steps.
Sure Steps provides your patients with educational materials, online tools, and nurse counselors to answer their questions about pulmonary arterial hypertension (PAH) and Actelion PAH therapies.
Patients must enroll in Sure Steps to enjoy the many benefits of the program, including:
- Helpful information about what to expect from therapy
- Practical tips to help them make the most of therapy
There are a few ways your patients can receive the informative benefits of Sure Steps, including:
- Talking one-on-one over the phone to a PAH-trained Sure Steps nurse counselor
- Agreeing to receive informative Sure Steps mailers and e-mails
Sure Steps is for patients with PAH who have been prescribed an Actelion PAH therapy.
Encourage your patients to enroll in Sure Steps.
To talk to a Sure Steps counselor, call:
1-877-STEPS-50 (1-877-783-7750) Monday through Friday, 8 AM-11 PM (ET)/5 AM-8 PM (PT)
or call PAH Pathways at 1-866-ACTELION (228-3546).
Spanish-speaking counselors are also available.
For access to PATHwatch, click here.
Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class II-IV symptoms, to improve exercise ability and decrease the rate of clinical worsening. Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these potential benefits are sufficient to offset the risk of liver injury in WHO Class II patients, which may preclude future use as their disease progresses.
Tracleer Important Safety Information
Because of the associated risks, Tracleer may be prescribed only through the Tracleer Access Program. Potential for serious liver injury (including, after prolonged treatment, rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) – Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects – Pregnancy must be excluded and prevented through the use of reliable forms of birth control; monthly pregnancy tests should be obtained.
Contraindicated for use with cyclosporine A and glyburide.
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.
Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
Important safety information about Ventavis:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.
Please see full Prescribing Information